Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico

Denisse Añorve Bailon (), Javier Picó-Guzmán (), Sergio Cifuentes (), Rogelio Trejo (), Jeronimo Rodríguez Cid (), Juan Jose Juarez-Vignon Whaley (), Alan Alexis Heredia Zepeda (), Raquel Gerson (), Christian Patricio Camacho-Limas (), José Fabián Martínez-Herrera (), Diana Bonilla Molina (), Efraín Camarín Sánchez () and Daniela Shveid Gerson ()
Additional contact information
Denisse Añorve Bailon: ISSSTE, Centro Médico Nacional “20 de Noviembre”
Javier Picó-Guzmán: LifeSciences Consultants
Sergio Cifuentes: ISSSTE, Centro Médico Nacional “20 de Noviembre”
Rogelio Trejo: IMSS, Centro Médico Nacional Siglo XXI
Jeronimo Rodríguez Cid: Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas
Juan Jose Juarez-Vignon Whaley: Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas
Alan Alexis Heredia Zepeda: LifeSciences Consultants
Raquel Gerson: Centro Médico ABC
Christian Patricio Camacho-Limas: Centro Médico ABC
José Fabián Martínez-Herrera: Centro Médico ABC
Diana Bonilla Molina: Centro Médico ABC
Efraín Camarín Sánchez: Centro Médico ABC
Daniela Shveid Gerson: Centro Médico ABC

PharmacoEconomics - Open, 2024, vol. 8, issue 6, No 8, 869-885

Abstract: Abstract Introduction Lung cancer continues to be the leading cause of death among cancer patients worldwide. This study aimed to estimate the clinical, economic, and social burdens of stage IV non-small cell lung cancer (NSCLC) in private and public healthcare centers in Mexico, utilizing real-world evidence. Methods The study population included patients >18 years of age diagnosed with stage IV NSCLC who received cancer treatment at the Centro Médico Nacional Siglo XXI (IMSS), the Centro Médico Nacional “20 de Noviembre” (ISSSTE), the Mexican Institute of Respiratory Diseases (INER), and the Medical Center ABC (American British Cowdray) from 1 January 2019 to 31 December 2020. The analysis included evaluation of epidemiological data, treatment regimens, and clinical outcomes, and emphasized pharmacological and non-pharmacological treatments, including detailed follow-up investigations, as part of comprehensive clinical management. Additionally, the study assessed the social burden through variables such as working-age absenteeism and presenteeism and caregiver productivity loss, as well as economic burden, considering both clinical and social components, with costs adjusted to 2022 Mexican pesos (MXN) values. Results A total of 188 patients with metastatic NSCLC were studied. The main type of NSCLC tumor found in the sample was adenocarcinoma (81%). Treatment regimens included pharmacological treatments (78%), non-pharmacological treatments (25%), and palliative care (24%). Complications were present in 73% of the cohort, while 60% presented adverse events. Clinical management costs of up to MXN1,001,579 per patient in the public sector and MXN2,140,604 in the private sector were reported. It was estimated that working-age patients lose 84–335 days yearly due to absenteeism and presenteeism, while caregivers report a productivity loss equivalent to 13–30 days due to the management of NSCLC patients. These indirect costs of NSCLC contribute to the social burden. A working-age patient with stage IV disease is associated with an average indirect cost of MXN49,731–178,287 in public institutions, while in private institutions, the cost elevates to MXN438,103. Conclusions This study highlights the substantial clinical, economic, and social burdens of stage IV NSCLC in Mexico, revealing significant disparities between public and private healthcare sectors. It underscores the urgent need for standardized practices and equitable care across all systems.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00514-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00514-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00514-6

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().